LOGIN  |  REGISTER
Assertio
Terns Pharmaceuticals

Alignment Healthcare to Participate in the William Blair 43rd Annual Growth Stock Conference and Goldman Sachs 44th Annual Global Healthcare Conference

May 24, 2023 | Last Trade: US$19.48 0.05 0.26

ORANGE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), a tech-enabled Medicare Advantage company, today announced that John Kao, founder and CEO, and Thomas Freeman, chief financial officer, will participate in the following conferences:

  • William Blair 43rd Annual Growth Stock Conference, including a presentation on Wednesday, June 7, at 11:20 a.m. CDT
  • Goldman Sachs 44th Annual Global Healthcare Conference, including a presentation on Tuesday, June 13, at 11:20 a.m. PDT

A webcast and replay of the presentations will be available on Alignment’s investor relations website at https://ir.alignmenthealth.com/.

About Alignment Healthcare

Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health is a tech-enabled Medicare Advantage company that offers more than 40 benefits-rich, value-driven plans that serve 52 counties across six states. The company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. Based in California, the company’s mission-focused team makes high-quality, low-cost care a reality for members every day. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com.

Investor Contact
Harrison Zhuo
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Maggie Habib
mPR, Inc. for Alignment Healthcare
This email address is being protected from spambots. You need JavaScript enabled to view it.

Astria Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page